Acrodermatitis chronica atrophicans epidemiology and demographics

Revision as of 10:43, 3 June 2021 by Anahita (talk | contribs) (→‎Age)
Jump to navigation Jump to search

Acrodermatitis chronica atrophicans Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Acrodermatitis chronica atrophicans from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Acrodermatitis chronica atrophicans epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Acrodermatitis chronica atrophicans epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Acrodermatitis chronica atrophicans epidemiology and demographics

CDC on Acrodermatitis chronica atrophicans epidemiology and demographics

Acrodermatitis chronica atrophicans epidemiology and demographics in the news

Blogs on Acrodermatitis chronica atrophicans epidemiology and demographics

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Acrodermatitis chronica atrophicans epidemiology and demographics


Xyz Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Xyz from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Acrodermatitis chronica atrophicans epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Acrodermatitis chronica atrophicans epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Acrodermatitis chronica atrophicans epidemiology and demographics

CDC on Acrodermatitis chronica atrophicans epidemiology and demographics

Acrodermatitis chronica atrophicans epidemiology and demographics in the news

Blogs on Acrodermatitis chronica atrophicans epidemiology and demographics

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Acrodermatitis chronica atrophicans epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Anahita Deylamsalehi, M.D.[2]

Overview

Epidemiology and Demographics

Incidence

  • The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.

Prevalence

  • The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
  • The prevalence of [disease/malignancy] is estimated to be [number] cases annually.

Case-fatality rate/Mortality rate

  • The case-fatality rate/mortality rate of [disease name] is approximately [number range].

Age

Race

  • [Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].

Gender

Region


References

  1. 1.0 1.1 1.2 1.3 1.4 Khalili M, Wong RJ (2018). "Underserved Does Not Mean Undeserved: Unfurling the HCV Care in the Safety Net". Dig Dis Sci. 63 (12): 3250–3252. doi:10.1007/s10620-018-5316-9. PMC 6436636. PMID 30311153.
  2. THYRESSON N (1949). "The penicillin treatment of acrodermatitis atrophicans chronica (Herxheimer)". Acta Derm Venereol. 29 (6): 572–621. PMID 18140373.
  3. Asbrink E, Hovmark A, Olsson I (1986). "Clinical manifestations of acrodermatitis chronica atrophicans in 50 Swedish patients". Zentralbl Bakteriol Mikrobiol Hyg A. 263 (1–2): 253–61. doi:10.1016/s0176-6724(86)80128-6. PMID 3577484.
  4. Weber K, Preac-Mursic V, Neubert U, Thurmayr R, Herzer P, Wilske B; et al. (1988). "Antibiotic therapy of early European Lyme borreliosis and acrodermatitis chronica atrophicans". Ann N Y Acad Sci. 539: 324–45. doi:10.1111/j.1749-6632.1988.tb31867.x. PMID 3056202.

Template:WH Template:WS